
Commentary|Podcasts|November 18, 2025
Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition
Fact checked by: Ron Panarotti
Advertisement
This week, host Craig Beavers spoke with Joe Saseen, PharmD, BCPS, BCACP, CLS, about several key trials presented at the American Heart Association 2025 Scientific Sessions.
Show notes:
- VESALIUS-CV trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 CORAL REEF trial
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
Dosing, Monitoring, and Counseling: The Pharmacist's Role in TKI Therapy for Systemic Mastocytosis
5





































































































